



MAYNE PHARMA LAUNCHES MORPHINE SULFATE EXTENDED-RELEASE TABLETS IN THE US

3 November 2016, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the launch of morphine sulfate extended-release (MSER) tablets (15mg, 30mg, 60mg and 100mg) in the United States. Mayne Pharma received approval from the US Food and Drug Administration for its Abbreviated New Drug Application (ANDA), which is a generic version of MS Contin®, an opioid analgesic for moderate to severe pain management. According to IMS Health, US brand and generic sales of MSER tablets were approximately US\$280 million for the 12 months ending 31 August 2016.

Mayne Pharma's CEO, Mr Scott Richards, said "This launch supports our growth and underscores our investment and commitment to bringing complex generic products to the marketplace. A key focus of our generic development program has been to expand our product offering by focusing on complex formulations such as modified-release, potent compounds and controlled substances. It is pleasing to report that our Generic Products Division now directly markets more than 50 products and we have a growing pipeline of more than 40 generic and branded drug products targeting US markets with IMS sales greater than US\$7 billion."

For further information contact:

Lisa Pendlebury +61 419 548 434, lisa.pendlebury@maynepharma.com

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, providing patients with access to better and more affordable medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 30-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that have been marketed around the world.

Mayne Pharma has two product development and manufacturing facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral dose forms including highly potent compounds, controlled substances, modified-release products and inherently unstable compounds.

MS Contin® is a registered trademark in the US of Purdue Pharma L.P.

